• 研究室検索
  • 分子病態治療学(附属創生応用医学研究センター)


Molecular Medicine and Therapy(United Centers for Advanced Research and Translational Medicine)分子病態治療学(附属創生応用医学研究センター)

  • 医薬品
  • 人工知能
  • プログラム医療機器
  • PAI-1阻害薬
  • メディシナルハブ



  • Miyata, ToshioProfessor. 宮田 敏男 教授

Other Faculty / Staff

  • Asakura, Takayoshi
    Specially Appointed Associate Professor. 朝倉 敬喜 特任准教授
  • Ui, Mihoko
    Assistant Prof. 宇井 美穂子 助教




In recent years, treatment modalities have diversified, and pharmaceuticals are also focusing on biopharmaceuticals such as antibody drugs, nucleic acid drugs, cell drugs, and gene therapy. In addition to pharmaceuticals, medical devices and even medical solutions utilizing artificial intelligence (AI) are attracting attention, and a framework for efficiently and quickly researching and developing various modalities has become important. The speed at which cutting-edge science and technology are applied to medical care and implemented in society is accelerating, and collaboration through specialization, division of labor, and fusion of different fields is becoming essential. The target of treatment is also focused on individualization from blockbusters that target many patients. The role of academia as a bearer of innovation is also increasing in importance. The role played by academia is also expanding, such as exploratory clinical research in doctor-initiated clinical trials, accumulation of medical big data, and creation of bio-ventures. Along with this, in addition to chemistry and biology, engineering and information science and technology, as well as their interdisciplinary combinations, are considered important. Our laboratory utilizes the Medicinal-hub, an open innovation platform in Tohoku Unoversity, to develop pharmaceuticals and AI-programmed medical devices.


  • Medicinal-hub(open innovation platform)

  • Laboratory


Takahashi N, et al. Deep molecular response in patients with chronic phase chronic myeloid leukemia treated with the plasminogen activator inhibitor-1 inhibitor TM5614 combined with a tyrosine kinase inhibitor. Cancer Medicine. 9: 23, 2022

Hirai S , et al. High-sucrose diets contribute to brain angiopathy with impaired glucose uptake and psychosis-related higher brain dysfunctions in mice. Science Advances 7, eabl6077, 2021

Toriumi K, et al. Combined glyoxalase 1 dysfunction and vitamin B6 deficiency in a schizophrenia model system causes mitochondrial dysfunction in the prefrontal cortex. Redox Biol. 45: 102057, 2021

Khan SS, et al. A null mutation in SERPINE1 protects against biological aging in humans. Science Advances 3: eaao1617, 2017

Eren M, et al. PAI-1 is a critical regulator of FGF23 homeostasis. Science Advances 3: e1603259, 2017